Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06733441 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Site details revised at 5 of 5 sitesv10 Show 1 more changeShow less
    • Site details revised at 5 of 5 sites
  2. Re-verified, no change to tracked fieldsv9
  3. Study sites: 4 to 5v8
  4. Site contacts updated at 1 of 4 sitesv7
  5. Study sites: 2 to 4v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study Identification, Study Status, Oversight, Study Designv5
  2. Study sites: 1 to 2v4
  3. Trial status: Not Yet Recruiting to Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  4. Study Identification, Study Status, Oversight, Eligibilityv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Trial Details
NCT Number NCT06733441
Lead Sponsor Treeline Biosciences, Inc.
Conditions Lymphoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov